Rosa M. Morillas

β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

Càndid Villanueva, Agustı́n Albillos, Joan Genescà et al. · The Lancet · 2019 · 638 citations

Hypertension, Hepatology, Antihypertensive Therapy +8

Natural History of Patients Hospitalized for Management of Cirrhotic Ascites

Ramón Planas, Silvia Montoliu, Belén Ballesté et al. · Clinical Gastroenterology and Hepatology · 2006 · 397 citations

Hepatology, Natural History, Patient Safety +3

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Xavier Forns, Samuel S. Lee, Joaquin Valdes et al. · The Lancet Infectious Diseases · 2017 · 338 citations

Hepatology, Hepatitis C, Viral Hepatitis +11

Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis

Juan G. Abraldeṣ, Càndid Villanueva, Carles Aracil et al. · Gastroenterology · 2016 · 322 citations

Increases Survival, Hepatology, Variceal Rebleeding Does +4

Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis

Annalisa Berzigotti, Guadalupe García–Tsao, Jaime Bosch et al. · Hepatology · 2011 · 307 citations · Full text